Bitzer Johannes, Paoletti Anna M
Department of Obstetrics and Gynecology, University Hospital Basel, Basel, Switzerland.
Clin Drug Investig. 2009;29(2):73-8. doi: 10.2165/0044011-200929020-00001.
The ethinylestradiol 20 microg/drospirenone 3 mg combined oral contraceptive (COC), administered in cycles of 21 days continuous use followed by a 7-day hormone-free interval (21/7) [Yasminelle], has been proven to be an effective and well tolerated contraceptive with an acceptable bleeding pattern and good safety profile. In addition, the ethinylestradiol 20 microg/drospirenone 3 mg 21/7 COC prevents water-retention-related weight gain, and improves physical and emotional well-being, consistent with other drospirenone-containing COCs. In clinical studies, >85% of those who received the ethinylestradiol 20 microg/drospirenone 3 mg 21/7 COC were satisfied or very satisfied with this contraceptive. The positive attributes of the ethinylestradiol 20 microg/drospirenone 3 mg 21/7 COC beyond contraceptive protection may have important implications for improving treatment compliance and reducing treatment discontinuation. Physical well-being stayed the same or improved during use of this COC in 56% and 34% of women, respectively. Emotional well-being stayed the same or improved in 71% and 20% of women, respectively.
炔雌醇20微克/屈螺酮3毫克复方口服避孕药（COC），采用连续服用21天随后7天无激素间隔的周期给药方式（21/7）[Yasminelle]，已被证明是一种有效且耐受性良好的避孕药，具有可接受的出血模式和良好的安全性。此外，炔雌醇20微克/屈螺酮3毫克21/7 COC可防止与水潴留相关的体重增加，并改善身体和情绪健康，这与其他含屈螺酮的COC一致。在临床研究中，超过85%接受炔雌醇20微克/屈螺酮3毫克21/7 COC的人对这种避孕药感到满意或非常满意。炔雌醇20微克/屈螺酮3毫克21/7 COC除避孕保护作用外的积极特性可能对提高治疗依从性和减少治疗中断具有重要意义。在使用这种COC期间，分别有56%和34%的女性身体状况保持不变或有所改善。分别有71%和20%的女性情绪状况保持不变或有所改善。
